Healthline

All About Cyltezo

Cyltezo (adalimumab-adbm) is a prescription drug that’s used to treat certain autoimmune conditions, including ulcerative colitis and plaque psoriasis. Cyltezo comes as a liquid solution inside a ...
Medical News Today

Cyltezo dosage

Cyltezo (adalimumab-adbm) is a brand-name drug prescribed for several inflammatory conditions. Cyltezo comes as a liquid solution given by subcutaneous injection. It’s available as a single-dose ...
JD Supra

FDA Approves the Cyltezo Pen, an autoinjector option for Adalimumab

On May 22, 2023, Boehringer Ingelheim announced that the FDA has approved the Cyltezo Pen, a new autoinjector option for Cyltezo (adalimumab-adbm). According to a previous announcement from Boehringer ...
Monthly Prescribing Reference

Biosimilar Cyltezo Now Available in High-Concentration Formulation

Credit: Boehringer Ingeheim. The high-concentration formultion (100mg/mL) is available as a prefilled syringe (40mg/0.4mL) or prefilled autoinjector. Cyltezo is an interchangeable biosimilar and can ...
Yahoo Finance

FDA approves Boehringer Ingelheim’s Cyltezo for inflammatory ailments

The US Food and Drug Administration (FDA) has approved Boehringer Ingelheim's high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), an interchangeable biosimilar to Humira ...
Drug Store News

7 companies are rolling out Humira biosimilars

As widely expected by the pharmaceutical industry, seven pharmaceutical companies are releasing biosimilars of AbbVie's Humira. Boehringer Ingelheim's Cyltezo (adalimumab-adbm), an interchangeable ...
Healio

FDA approves autoinjector option for upcoming adalimumab biosimilar

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a new autoinjector pen option for Cyltezo, an interchangeable biosimilar to Humira. Cyltezo ...
Mena FN

Cyltezo®, First And Only Fda-Approved Interchangeable Biosimilar To Humira®, Now Commercially Available In The U.S.

boehringer ingelheim announced today that cyltezo® (adalimumab-adbm), a u.s. food and drug administration (fda)-approved interchangeable biosimilar to humira® (adalimumab), is now commercially ...
Healio

FDA approves high-concentration, citrate-free form of interchangeable biosimilar Cyltezo

Please provide your email address to receive an email when new articles are posted on . As with the low-concentration (50 mg/mL) version of Cyltezo (adalimumab-adbm ...
JD Supra

HUMIRA (adalimumab) Biosimilar Launches

In the last week, seven adalimumab biosimilars referencing HUMIRA entered the U.S. market: Boehringer Ingelheim’s CYLTEZO (adalimumab-adbm); Sandoz’s HYRIMOZ (adalimumab-adaz); Organon and Samsung ...
ksn.com

Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.

RIDGEFIELD, Conn., July 1, 2023 /PRNewswire/ -- Boehringer Ingelheim announced today that Cyltezo ® (adalimumab-adbm), a U.S. Food and Drug Administration (FDA)-approved Interchangeable biosimilar to ...